1. From the Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, UCSF/Mt. Zion Comprehensive Cancer Center, University of California San Francisco, California (SRH, MRC, EPE, DPL, MVM, PRC), and TAP Pharmaceutical Products, Inc., Lake Forest, Illinois (SSM)